{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:16:54Z","timestamp":1792707414118,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["burnsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.burns.2013.06.015","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T12:45:13Z","timestamp":1374237913000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Amikacin population pharmacokinetics among paediatric burn patients"],"prefix":"10.1016","volume":"40","author":[{"given":"Catherine M.T.","family":"Sherwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Spigarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2013.06.015_bib0005","first-page":"603","article-title":"The necessity of increased doses of amikacin in burn patients","volume":"84","author":"Zaske","year":"1978","journal-title":"Surgery"},{"key":"10.1016\/j.burns.2013.06.015_bib0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000658-199601000-00004","article-title":"Current treatment of severely burned patients","volume":"223","author":"Nguyen","year":"1996","journal-title":"Ann Sur"},{"key":"10.1016\/j.burns.2013.06.015_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/44.3.319","article-title":"Pharmacokinetics of antibiotics in burn patients","volume":"44","author":"Weinbren","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/AAC.32.2.236","article-title":"Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis","volume":"32","author":"Smeltzer","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/clinids\/14.2.458","article-title":"Pharmacokinetics of systemically administered antibiotics in patients with thermal injury","volume":"14","author":"Boucher","year":"1992","journal-title":"Clinical Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-199529010-00003","article-title":"Clinical pharmacokinetics in patients with burns","volume":"29","author":"Jaehde","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.burns.2013.06.015_bib0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/28.5.747","article-title":"Increased dosing requirements for amikacin in burned children","volume":"28","author":"Kopcha","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/clinids\/24.5.796","article-title":"A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Ali","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0045","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.34.4.614","article-title":"Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity","volume":"34","author":"Garraffo","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00003088-200847100-00002","article-title":"Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients","volume":"47","author":"Blanchet","year":"2008","journal-title":"Clin Pharmacokin"},{"issue":"Suppl. 2","key":"10.1016\/j.burns.2013.06.015_bib0055","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1086\/426189","article-title":"Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections","volume":"40","author":"Burgess","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0060","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/infdis\/162.2.414","article-title":"Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation","volume":"162","author":"Daikos","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0891-5520(05)70259-2","article-title":"Once-daily dosing of aminoglycoside antibiotics","volume":"14","author":"Fisman","year":"2000","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.burns.2013.06.015_bib0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1875-9114.1997.tb03063.x","article-title":"Aminoglycoside adaptive resistance","volume":"17","author":"Karlowsky","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.burns.2013.06.015_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/AAC.35.1.117","article-title":"First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use","volume":"35","author":"Daikos","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/13.suppl_A.9","article-title":"Aminoglycoside toxicity \u2013 a review of clinical studies published between 1975 and 1982","volume":"13 (Suppl. A)","author":"Kahlmeter","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/27.suppl_C.41","article-title":"Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man","volume":"27 (Suppl. C)","author":"De Broe","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/AAC.27.4.520","article-title":"Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans","volume":"27","author":"Contrepois","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0095","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.31.4.570","article-title":"Correlation between renal membrane binding and nephrotoxicity of aminoglycosides","volume":"31","author":"Williams","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.heares.2006.05.008","article-title":"Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic","volume":"226","author":"Chen","year":"2007","journal-title":"Hear Res"},{"key":"10.1016\/j.burns.2013.06.015_bib0105","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.9.6.956","article-title":"Ototoxicity of amikacin","volume":"9","author":"Black","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-199936020-00001","article-title":"Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?","volume":"36","author":"Barclay","year":"1999","journal-title":"Clin Pharmacokin"},{"key":"10.1016\/j.burns.2013.06.015_bib0115","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/ajhp\/53.10.1141","article-title":"Effectiveness and safety of once-daily aminoglycosides: a meta-analysis","volume":"53","author":"Ferriols-Lisart","year":"1996","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.burns.2013.06.015_bib0120","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/clinchem\/27.7.1190","article-title":"Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma","volume":"27","author":"Jolley","year":"1981","journal-title":"Clin Chem"},{"key":"10.1016\/j.burns.2013.06.015_bib0125","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics I: background, concepts, and models","volume":"38","author":"Ette","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.burns.2013.06.015_bib0130","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1093\/infdis\/135.Supplement_2.S312","article-title":"Clinical pharmacology of amikacin and kanamycin","volume":"134 (Suppl.)","author":"Kirby","year":"1976","journal-title":"J Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/27.suppl_C.63","article-title":"Pharmacokinetic evaluation of single daily dose amikacin","volume":"27 (Suppl. C)","author":"Van der Auwera","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jac\/5.1.95","article-title":"The pharmacokinetics of amikacin and gentamicin in volunteers: a comparison of individual differences","volume":"5","author":"Walker","year":"1979","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0145","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1128\/AAC.00374-11","article-title":"Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration","volume":"55","author":"Akers","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2006.04.015","article-title":"Increased amikacin dosage requirements in burn patients receiving a once-daily regimen","volume":"28","author":"Conil","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.burns.2013.06.015_bib0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/j.1552-4604.1991.tb03700.x","article-title":"Amikacin pharmacokinetics: wide interpatient variation in 98 patients","volume":"31","author":"Zaske","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.burns.2013.06.015_bib0160","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1128\/AAC.40.7.1682","article-title":"Population pharmacokinetics of amikacin in critically ill patients","volume":"40","author":"Bressolle","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/44.2.235","article-title":"Population pharmacokinetics of amikacin in patients with haematological malignancies","volume":"44","author":"Romano","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0170","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00228-009-0637-4","article-title":"Individualised dosing of amikacin in neonates: a pharmacokinetic\/pharmacodynamic analysis","volume":"65","author":"Sherwin","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.burns.2013.06.015_bib0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01086153","article-title":"Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients","volume":"4","author":"Sawchuk","year":"1976","journal-title":"J Pharmacokin Biopharm"},{"key":"10.1016\/j.burns.2013.06.015_bib0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/00005373-197610000-00014","article-title":"Increased dosage requirements of gentamicin in burn patients","volume":"16","author":"Zaske","year":"1976","journal-title":"J Trauma"},{"key":"10.1016\/j.burns.2013.06.015_bib0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","article-title":"Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance","volume":"51","author":"De Cock","year":"2012","journal-title":"Clin Pharmacokin"},{"key":"10.1016\/j.burns.2013.06.015_bib0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.burns.2008.05.016","article-title":"Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn","volume":"35","author":"Yang","year":"2009","journal-title":"Burns"},{"key":"10.1016\/j.burns.2013.06.015_bib0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1211\/0022357021778781","article-title":"Effect of unilateral nephrectomy on the pharmacokinetics of amikacin in humans","volume":"54","author":"Drozdzik","year":"2002","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.burns.2013.06.015_bib0200","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1128\/AAC.35.5.944","article-title":"Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy","volume":"35","author":"Davis","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0205","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2165\/00003088-197803030-00002","article-title":"Why monitor serum levels of gentamicin?","volume":"3","author":"Barza","year":"1978","journal-title":"Clin Pharmacokin"},{"key":"10.1016\/j.burns.2013.06.015_bib0210","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1128\/AAC.31.11.1855","article-title":"Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients","volume":"31","author":"Hassan","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.burns.2013.06.015_bib0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0220","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/CCM.0b013e3181cc4824","article-title":"Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department","volume":"38","author":"Gaieski","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.burns.2013.06.015_bib0225","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.burns.2013.06.015_bib0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417913001988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417913001988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:27:01Z","timestamp":1715740021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417913001988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0305417913001988"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2013.06.015","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amikacin population pharmacokinetics among paediatric burn patients","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2013.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd and ISBI. All rights reserved.","name":"copyright","label":"Copyright"}]}}